Characterization of antibodies that detect human GFAP after traumatic brain injury

Biomarker Insights

Volumn 7, Issue , 2012, Pages 71-79

  Susie Zoltewicz, J ^a   Scharf, Dancia ^b   Yang, Boxuan ^a   Chawla, Aarti ^c   Newsom, Kimberly J ^a   Fang, Lijuan ^a  

^a BANYAN BIOMARKERS INC   (United States)

^b Banyan Biomarkers Inc   (United States)

^c Banyan Biomarkers Inc   (United States)

Author keywords

GFAP; GFAP BDP; Human; Traumatic brain injury

Indexed keywords

CALPAIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC PROTEIN; PROTEIN S100B;

ANTIBODY DETECTION; ARTICLE; CELL LYSATE; CEREBROSPINAL FLUID ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; TRAUMATIC BRAIN INJURY;

EID: 84863937903     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S9873     Document Type: Article

References (31)

1. Williams AJ, Hartings JA, Lu XC, Rolli ML, Tortella FC. Penetrating ballistic-like brain injury in the rat: differential time courses of hemorrhage, cell death, inflammation, and remote degeneration. J Neurotrauma. Dec 2006; 23(12):1828-46.
2. Mondello S, Muller U, Jeromin A, Streeter J, Hayes RL, Wang KK. Bloodbased diagnostics of traumatic brain injuries. Expert Rev Mol Diagn. Jan 2011; 11(1):65-78.
3. Wang KK. Calpain and caspase: can you tell the difference? Trends Neurosci. Jan 2000;23(1):20-6.
4. Liu MC, Akle V, Zheng W, et al. Comparing calpain-and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem J. Mar 15, 2006;394(Pt 3):715-25.
5. Camins A, Verdaguer E, Folch J, Pallas M. Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev. Summer 2006;12(2): 135-48.
6. Kupina NC, Nath R, Bernath EE, et al. The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J Neurotrauma. Nov 2001;18(11):1229-40.
7. Zhang Z, Ottens AK, Sadasivan S, et al. Calpain-mediated collapsin response mediator protein-1,-2, and-4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma. Mar 2007;24(3):460-72.
8. Brophy GM, Mondello S, Papa L, et al. Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in Severe Traumatic Brain Injury Patient Biofluids. J Neurotrauma. Jun 2011;28(6):861-70.
9. Brophy GM, Pineda JA, Papa L, et al. AlphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. Apr 2009; 26(4):471-9.
10. Mondello S, Robicsek SA, Gabrielli A, et al. AlphaII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma. Jul 2010;27(7):1203-13.
11. Siman R, Toraskar N, Dang A, et al. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma. Nov 2009; 26(11):1867-77.
12. Berger RP, Adelson PD, Richichi R, Kochanek PM. Serum biomarkers after traumatic and hypoxemic brain injuries: insight into the biochemical response of the pediatric brain to inflicted brain injury. Dev Neurosci. 2006; 28(4-5):327-35.
13. Anderson KJ, Scheff SW, Miller KM, et al. The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J Neurotrauma. Sep 2008;25(9):1079-85.
14. Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of alphaIIspectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. Feb 2007;24(2):354-66.
15. Papa L, Akinyi L, Liu MC, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med. Jan 2010;38(1):138-44.
16. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. Oct 31, 1996;335(18):1342-9.
17. Papa L, Lewis LM, Falk JL, et al. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med. Nov 8, 2011.
18. Vos PE, Jacobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. Nov 16, 2010;75(20):1786-93.
19. Pelinka LE, Kroepfl A, Schmidhammer R, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma. Nov 2004;57(5):1006-12.
20. Lumpkins KM, Bochicchio GV, Keledjian K, Simard JM, McCunn M, Scalea T. Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma. Oct 2008;65(4):778-82; discussion 782-74.
21. Vos PE, Lamers KJ, Hendriks JC, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology. Apr 27, 2004;62(8):1303-10.
22. van Geel WJ, de Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta. Dec 2002;326(1-2):151-4.
23. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma. Nov 2004;21(11):1553-61.
24. Nylen K, Ost M, Csajbok LZ, et al. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci. Jan 15, 2006;240(1-2):85-91.
25. Mondello S, Papa L, Buki A, et al. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care. Jun 24, 2011;15(3):R156.
26. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. Nov 2000;31(11):2670-7.
27. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirtyone years (1969-2000). Neurochem Res. Oct 2000;25(9-10):1439-51.
28. Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. Mar 2011;93(3):421-43.
29. Martinez JA, Zhang Z, Svetlov SI, Hayes RL, Wang KK, Larner SF. Calpain and caspase processing of caspase-12 contribute to the ER stress-induced cell death pathway in differentiated PC12 cells. Apoptosis. Dec 2010;15(12): 1480-93.
30. Wang KK, Nath R, Raser KJ, Hajimohammadreza I. Maitotoxin induces calpain activation in SH-SY5Y neuroblastoma cells and cerebrocortical cultures. Arch Biochem Biophys. Jul 15, 1996;331(2):208-14.
31. Zhang Z, Larner SF, Liu MC, Zheng W, Hayes RL, Wang KK. Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis. Nov 2009; 14(11):1289-98.